Omega-3-acid ethyl esters
- Generic Name
- Omega-3-acid ethyl esters
- Brand Names
- Lovaza, Omtryg
- Drug Type
- Small Molecule
- CAS Number
- 308081-97-2
- Unique Ingredient Identifier
- D87YGH4Z0Q
- Background
Omega-3-acid ethyl esters are prescription drugs that contain eicosapentaenoic acid-ethyl ester (EPA) and docosahexaenoic acid-ethyl ester (DHA) that are used in combination with changes in diet to lower triglyceride levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia. Omega-3-acid ethyl esters are currently marketed in the US, EU, and many other regions under the brand name Lovaza.
- Indication
Omega-3-Acid Ethyl Esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG).
- Associated Conditions
- Severe Hypertriglyceridemia (sHTG)
Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia
- Conditions
- Hypertriglyceridemia
- Interventions
- First Posted Date
- 2007-02-14
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 245
- Registration Number
- NCT00435045
Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation
- Conditions
- Fibrillation, Atrial
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 663
- Registration Number
- NCT00402363
- Locations
- 🇺🇸
GSK Investigational Site, Wausau, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.